These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9990073)

  • 21. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
    Tine JA; Lanar DE; Smith DM; Wellde BT; Schultheiss P; Ware LA; Kauffman EB; Wirtz RA; De Taisne C; Hui GS; Chang SP; Church P; Hollingdale MR; Kaslow DC; Hoffman S; Guito KP; Ballou WR; Sadoff JC; Paoletti E
    Infect Immun; 1996 Sep; 64(9):3833-44. PubMed ID: 8751936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.
    BenMohamed L; Thomas A; Druilhe P
    Infect Immun; 2004 Aug; 72(8):4376-84. PubMed ID: 15271893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclusion of an Optimized
    Eacret JS; Parzych EM; Gonzales DM; Burns JM
    J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984
    [No Abstract]   [Full Text] [Related]  

  • 24. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.
    Perlaza BL; Sauzet JP; Balde AT; Brahimi K; Tall A; Corradin G; Druilhe P
    Eur J Immunol; 2001 Jul; 31(7):2200-9. PubMed ID: 11449374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3.
    Aidoo M; Lalvani A; Gilbert SC; Hu JT; Daubersies P; Hurt N; Whittle HC; Druihle P; Hill AV
    Infect Immun; 2000 Jan; 68(1):227-32. PubMed ID: 10603392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces
    Bjerkan L; Visweswaran GRR; Gudjonsson A; Labbé GM; Quinkert D; Pattinson DJ; Spång HCL; Draper SJ; Bogen B; Braathen R
    Front Immunol; 2021; 12():720550. PubMed ID: 34733274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
    PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India.
    Joshi SK; Bharadwaj A; Chatterjee S; Chauhan VS
    Infect Immun; 2000 Jan; 68(1):141-50. PubMed ID: 10603380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
    Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
    J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
    J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
    de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
    Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
    Nardin E; Munesinghe YD; Moreno A; Clavijo P; Calle MC; Edelman R; Davis J; Herrington D; Nussenzweig RS
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():223-7. PubMed ID: 1364202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.
    Iyori M; Nakaya H; Inagaki K; Pichyangkul S; Yamamoto DS; Kawasaki M; Kwak K; Mizukoshi M; Goto Y; Matsuoka H; Matsumoto M; Yoshida S
    PLoS One; 2013; 8(8):e70819. PubMed ID: 23951015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.
    Olugbile S; Kulangara C; Bang G; Bertholet S; Suzarte E; Villard V; Frank G; Audran R; Razaname A; Nebie I; Awobusuyi O; Spertini F; Kajava AV; Felger I; Druilhe P; Corradin G
    Infect Immun; 2009 Dec; 77(12):5701-9. PubMed ID: 19786562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic peptides based on conserved Plasmodium falciparum antigens are immunogenic and protective against Plasmodium yoelii malaria.
    Chauhan VS; Chatterjee S; Johar PK
    Parasite Immunol; 1993 Apr; 15(4):239-42. PubMed ID: 7685076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.